Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development
- PMID: 18043260
- DOI: 10.1097/CCO.0b013e3282f3111e
Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development
Abstract
Purpose of review: The phosphoinositide 3-kinases are lipid kinases that are activated in response to external factors. They regulate a number of intracellular signaling pathways involved in cell motility, metabolism, survival, and growth. This review summarizes the current knowledge about specific contributions of Class IA phosphoinositide 3-kinases to tumorigenesis and presents a rationale for the development of isoform-specific inhibitors.
Recent findings: In the last decade, the Class IA phosphoinositide 3-kinases have gained considerable attention as drug targets for the treatment of cancer. Indeed, pan-phosphoinositide 3-kinase inhibitors are being evaluated in early phases of clinical trials for the treatment of multiple human malignancies. Accumulating evidence suggests that selectively targeting individual isoforms is also possible. However, the patient population that is most likely to benefit from such selective compounds remains to be elucidated.
Summary: Given the importance of the phosphoinositide 3-kinase pathway in the initiation and maintenance of human tumors, drugs that effectively target its constituents will be an invaluable addition to the arsenal of anticancer therapeutics. However, to fully capitalize on the central role of this pathway in malignancy, we must first fully understand the nuances of its multiple players.
Similar articles
-
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.Semin Oncol. 2006 Aug;33(4):407-20. doi: 10.1053/j.seminoncol.2006.04.005. Semin Oncol. 2006. PMID: 16890796 Review.
-
Targeting phosphoinositide 3-kinase gamma to fight inflammation and more.Thromb Haemost. 2008 Feb;99(2):279-85. doi: 10.1160/TH07-10-0632. Thromb Haemost. 2008. PMID: 18278175 Review.
-
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.Curr Opin Cell Biol. 2009 Apr;21(2):194-8. doi: 10.1016/j.ceb.2008.12.011. Epub 2009 Feb 7. Curr Opin Cell Biol. 2009. PMID: 19201591 Review.
-
Drug discovery approaches targeting the PI3K/Akt pathway in cancer.Oncogene. 2008 Sep 18;27(41):5511-26. doi: 10.1038/onc.2008.246. Oncogene. 2008. PMID: 18794885 Review.
-
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.J Clin Oncol. 2003 May 15;21(10 Suppl):175s-186s. doi: 10.1200/JCO.2003.01.146. J Clin Oncol. 2003. PMID: 12743132 Review.
Cited by
-
Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports.Diagn Pathol. 2020 Sep 28;15(1):122. doi: 10.1186/s13000-020-01022-x. Diagn Pathol. 2020. PMID: 32988392 Free PMC article.
-
TGX-221 inhibits proliferation and induces apoptosis in human glioblastoma cells.Oncol Rep. 2017 Nov;38(5):2836-2842. doi: 10.3892/or.2017.5991. Epub 2017 Sep 22. Oncol Rep. 2017. PMID: 29048665 Free PMC article.
-
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.Oncotarget. 2014 Nov 30;5(22):11168-79. doi: 10.18632/oncotarget.2584. Oncotarget. 2014. PMID: 25426553 Free PMC article. Clinical Trial.
-
PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.J Neurooncol. 2011 Aug;104(1):155-67. doi: 10.1007/s11060-010-0492-2. Epub 2010 Dec 29. J Neurooncol. 2011. PMID: 21188471
-
Consensus model for identification of novel PI3K inhibitors in large chemical library.J Comput Aided Mol Des. 2010 Feb;24(2):131-41. doi: 10.1007/s10822-010-9321-0. Epub 2010 Feb 11. J Comput Aided Mol Des. 2010. PMID: 20148286
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
